Cargando…

Metastasis-directed therapy in castration-refractory prostate cancer (MEDCARE): a non-randomized phase 2 trial

BACKGROUND: Patients diagnosed with metastatic castration-refractory prostate cancer (mCRPC) rely on a limited number of therapeutic agents resulting in a median survival of 2–3 years. A subgroup of those patients with mCRPC presents with oligoprogressive disease, with a limited number of progressiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berghen, Charlien, Joniau, Steven, Rans, Kato, Devos, Gaëtan, Poels, Kenneth, Slabbaert, Koen, Dumez, Herlinde, Albersen, Maarten, Goffin, Karolien, Haustermans, Karin, De Meerleer, Gert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245754/ https://www.ncbi.nlm.nih.gov/pubmed/32448171 http://dx.doi.org/10.1186/s12885-020-06853-x

Ejemplares similares

Metastasis-directed therapy for oligometastatic urological tumours: still no second-hand news
por: Berghen, Charlien, et al.
Publicado: (2020)

SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?
por: Rans, Kato, et al.
Publicado: (2022)

Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy
por: Devos, Gaëtan, et al.
Publicado: (2020)

Parameters predicting [(18)F]PSMA-1007 scan positivity and type and number of detected lesions in patients with biochemical recurrence of prostate cancer
por: Ahmadi Bidakhvidi, Niloefar, et al.
Publicado: (2021)

Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer
por: Devos, Gaëtan, et al.
Publicado: (2019)

Metastasectomy of oligometastatic urothelial cancer: a single-center experience
por: Muilwijk, Tim, et al.
Publicado: (2020)

Penile metastasis in prostate cancer patients: Two case reports, surgical excision technique, and literature review
por: Landen, Lucas, et al.
Publicado: (2023)

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients
por: Giesen, Alexander, et al.
Publicado: (2023)

Benefits of Elective Para-Aortic Radiotherapy for pN1 Prostate Cancer Using Arc Therapy (Intensity-Modulated or Volumetric Modulated Arc Therapy): Protocol for a Nonrandomized Phase II Trial
por: Draulans, Cédric, et al.
Publicado: (2018)

(18)F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study
por: Emonds, Kimy M, et al.
Publicado: (2013)

Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study
por: Fonteyne, Valérie, et al.
Publicado: (2023)

Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
por: Tosco, Lorenzo, et al.
Publicado: (2018)

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial
por: Verghote, Flor, et al.
Publicado: (2021)

Accuracy of dynamic sentinel lymph node biopsy for inguinal lymph node staging in cN0 penile cancer
por: Gebruers, Juanito, et al.
Publicado: (2023)

Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis
por: Chys, Brecht, et al.
Publicado: (2020)

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2020)

PREDICT Prostate, a useful tool in men with low- and intermediate-risk prostate cancer who are hesitant between conservative management and active treatment
por: Devos, Gaëtan, et al.
Publicado: (2020)

Oligometastatic prostate cancer: Metastases-directed therapy?
por: Van Poppel, Hein, et al.
Publicado: (2016)

Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer
por: Seikkula, Heikki, et al.
Publicado: (2017)

Risk stratification tools in prostate cancer, where do we stand?
por: Clinckaert, Andries, et al.
Publicado: (2021)

Nine-year survival after iterative metastasectomies for renal cell carcinoma
por: de Oliveira, Tiago Ribeiro, et al.
Publicado: (2019)

Preclinical Models in Prostate Cancer: Resistance to AR Targeting Therapies in Prostate Cancer
por: Devlies, Wout, et al.
Publicado: (2021)

Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages ≥cT1b: a single institution, matched analysis
por: Veys, Ralf, et al.
Publicado: (2017)

Recall and recognition of in-game advertising: the role of game control
por: Herrewijn, Laura, et al.
Publicado: (2014)

Preclinical Evidence for the Benefits of Penile Rehabilitation Therapy following Nerve-Sparing Radical Prostatectomy
por: Albersen, M., et al.
Publicado: (2008)

Simultaneous (18)F-FDG PET/MR metabolic and structural changes in visual snow syndrome and diagnostic use
por: Van Laere, Koen, et al.
Publicado: (2022)

Anatomical mapping of lymph nodes in patients receiving salvage lymphadenectomy based on a positive 11C-choline positron emission tomography/computed tomography scan
por: Deconinck, Steven, et al.
Publicado: (2019)

Surgical Castration in Hormone-Refractory Metastatic Prostate Cancer Patients Can Be an Alternative for Medical Castration
por: Zaitsu, Masayoshi, et al.
Publicado: (2012)

Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses
por: Mehra, Niven, et al.
Publicado: (2022)

Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection
por: Moris, Lisa, et al.
Publicado: (2016)

Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer
por: Patel, Jesal C., et al.
Publicado: (2013)

Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer
por: Rathi, Nityam, et al.
Publicado: (2020)

Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma
por: Roussel, Eduard, et al.
Publicado: (2022)

“Scan-(pre)Plan-Treat” Workflow for Bone Metastases Using the Ethos Therapy System: A Single-Center, In Silico Experience
por: Oldenburger, Eva, et al.
Publicado: (2023)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Development of temporal lobe epilepsy during maintenance electroconvulsive therapy: A case of human kindling?
por: Schotte, Caroline, et al.
Publicado: (2019)

Automated treatment planning of prostate stereotactic body radiotherapy with focal boosting on a fast‐rotating O‐ring linac: Plan quality comparison with C‐arm linacs
por: De Roover, Robin, et al.
Publicado: (2021)

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
por: Dumez, Herlinde, et al.
Publicado: (2009)

Using Intervention Mapping to Develop an mHealth Intervention to Support Men Who Have Sex With Men Engaging in Chemsex (Budd): Development and Usability Study
por: Herrijgers, Corinne, et al.
Publicado: (2022)

On the optimal z-score threshold for SISCOM analysis to localize the ictal onset zone
por: De Coster, Liesbeth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_skag9d1m0kcoj9bskqt3hmd1tu